Status:
UNKNOWN
Tolerance and Pharmacokinetics of TQB2450
Lead Sponsor:
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions:
Tumor
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
To study the pharmacokinetic characteristics of TQB2450 in the human body, recommend a reasonable regimen for subsequent research.
Eligibility Criteria
Inclusion
- Patients with advanced malignancy diagnosed with pathology or cytology who have failed standard treatment or no standard treatment;
- 18-70 years old;Eastern Cooperative Oncology Group performance status:0-1,Life expectancy of more than 3 months;
- Main organs function is normal;
- Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped;
- Patients should be voluntary and sign the informed consents before taking part in the study;
Exclusion
- Patients who have received programmed cell death protein 1(PD-1) or programmed cell death protein ligand(PD-L1) antibody treatment;
- Patients who had any\> 3 degree immune-related adverse event during any previous immunotherapy received;
- Appeared severe hypersensitivity after taking other monoclonal antibody drugs;
- Other malignancies have been diagnosed in the past 2 years except cured or locally curable cancers, such as cutaneous or squamous cell carcinoma, superficial bladder cancer, cervical cancer or orthotopic carcinoma of the breast;
- Known spinal cord compression, cancer meningitis patients, new onset of central nervous system metastasis or stable control of symptoms in patients with brain metastases less than 4 weeks; asymptomatic and stable imaging without the need for corticosteroid treatment；
- Patients with hypothyroidism over 2 degrees;
- Patients with active, or who have had, and are likely to relapse, autoimmune diseases; the following patients are enrolled: skin disorders without systemic treatment (eg vitiligo, psoriasis, hair loss);
- Patients treated with glucocorticoids or other immunosuppressive agents within 4 weeks prior to dosing;
- Interstitial lung disease or non-contagious pneumonia (including past history and current illness); uncontrolled systemic diseases including diabetes, hypertension, pulmonary fibrosis, acute lung disease, etc. except for radiotherapy-induced interstitial pneumonitis;
- Serious chronic or active infections require systemic antibacterial, antifungal or antiviral treatment (allowing antiviral treatment in patients with hepatocellular carcinoma), including tuberculosis infection;
- Unstable pleural effusion, pericardial effusion or ascites;
- Significant cardiovascular diseases such as heart failure of New York Heart Academy(NYHA) Class 2 and above, myocardial infarction within the past 3 months, unstable arrhythmias (including QT interval ≥480 ms) or unstable Angina;
- Patients with immunodeficiency, including HIV positive or other acquired, congenital immunodeficiency disease, or organ transplant history;
- Hypertension (systolic BP ≥140 mmHg, diastolic BP ≥90 mmHg) still uncontrollable by one medication;
- Hepatitis B virus patients with active replication (DNA\> 500 cps / mL), hepatitis C;
- The first medication interval from the patient: the last chemotherapy for at least 4 weeks, biological products at least five half-lives;
- The first medication interval from the patient: the last chemotherapy for at least 4 weeks, biological products at least five half-lives;
- Inoculated with vaccine or attenuated vaccine within 4 weeks before first administration;
- Major surgery, or unhealed wounds, ulcers or fractures within 4 weeks prior to the first dose;
Key Trial Info
Start Date :
March 15 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 15 2019
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT03460457
Start Date
March 15 2018
End Date
March 15 2019
Last Update
March 9 2018
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.